Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Robert Schnarrs

Norfolk, VA Medical Doctor

NPI 1427059617 CMS profile 1288273

400 W Brambleton Ave, Ste 300, Norfolk, VA 23510

Open in the dashboard

General payments

$9,621

175 records reported · program years 2019–2025

Research payments

$1,500

Paid to them · 2 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$22,490 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Robert Schnarrs of Norfolk, VA is reported in the CMS Open Payments database as having received $9,621 across 175 general payments and $1,500 in research payments paid to them. Separately, studies naming them as principal investigator received $22,490 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

By program year

9 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $439 6
2024 General $2,561 23
2023 General $2,765 36
2022 General $950 28
2021 General $1,467 36
2021 Research $1,000 1
2020 General $1,006 26
2020 Research $500 1
2019 General $433 20

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Robert Schnarrs
  • Virginia median
  • Middle half of Virginia
  • National median

In program year 2025, general payments to Robert Schnarrs were reported at $439. Among 24,845 Virginia profiles paid that year, the median was $179 and the middle half received between $56 and $613.

Show as a table
Year Robert Schnarrs Virginia median Middle half National median
2019 $433 $162 $50–$582 $163
2020 $1,006 $111 $36–$367 $114
2021 $1,467 $125 $37–$450 $132
2022 $950 $149 $45–$527 $149
2023 $2,765 $161 $50–$554 $160
2024 $2,561 $171 $55–$585 $164
2025 $439 $179 $56–$613 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $2,411 35 payments
  2. Mentor Worldwide LLC $1,460 40 payments
  3. Allergan Inc. $1,191 34 payments
  4. Stryker Corporation $1,061 2 payments
  5. Musculoskeletal Transplant Foundation Inc. $872 4 payments
  6. Davol Inc. $622 7 payments
  7. Sientra, Inc. $314 6 payments
  8. Galderma Laboratories, L.P. $258 8 payments
  9. Smith+Nephew, Inc. $246 13 payments
  10. PolyNovo North America LLC $239 2 payments
  11. Other $946 24 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $6,473 169 payments
  2. Travel and Lodging $2,998 5 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $150 1 payment
Products named General payments · program years 2019–2025
  1. NATRELLE SALINE-FILLED BREAST IMPLANTS Plastic Surgery $1,927 12 payments
  2. STRATTICE RECONSTRUCTIVE TISSUE MATRIX BPS $1,871 8 payments
  3. MENTOR MemoryGel Resterilizable Gel Sizer $1,028 31 payments
  4. 1788 $779 1 payment
  5. NATRELLE $565 15 payments
  6. NATRELLE SALINE-FILLED BREAST IMPLANTS Plastics $483 10 payments
  7. SIENTRA HIGH STRENGTH COHESIVE SILICONE GEL BREAST IMPLANT $314 6 payments
  8. SPY-PHI SYSTEM $282 1 payment
  9. ARTOURA Breast Tissue Expander $269 6 payments
  10. Phasix Mesh $245 2 payments
  11. Other $2,550 80 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Sientra, Inc. $1,500 2 payments

Prescribing to Medicare patients

Part D · data year 2024 · 3 drugs

Part D claims

62

Median for Plastic and Reconstructive Surgery: 61

Drug cost

$363

Median for Plastic and Reconstructive Surgery: $369

Branded share of claims

24.2%

Median for Plastic and Reconstructive Surgery: 30%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ibuprofen Generic 26 $146
Cephalexin Generic 21 $136
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 15 $82

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,638 Part D prescribers listed as Plastic and Reconstructive Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 106 billing codes

Paid by Medicare

$75,190

Medicare's payments for the services billed

Medicare patients

137

Average age 74

Services billed

528

102 women, 35 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 55%
Cancer 46%
Diabetes 30%
Ischemic heart disease 23%
Chronic kidney disease 22%
Depression 20%
Osteoporosis 19%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

2 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
BOTOX
  • AbbVie, Inc. $47
$47 — —
DALVANCE
  • AbbVie, Inc. $16
$16 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

177 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record